BioSpace News Archive

Business

Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance

Company announces anticipated timelines for data readouts from six cabozantinib potentially label-enabling clinical studies and up to three new potential IND candidates

January 12, 2020
·
21 min read
Policy

Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog

Iovance Biotherapeutics, Inc. announced that the company has obtained a license from Novartis to develop and commercialize an antibody cytokine engrafted protein, referred to as IOV-3001.

January 12, 2020
·
6 min read
Business

Luminex Corporation Announces 2019 Highlights and 2020 Guidance; Company to Present at 38th Annual J.P. Morgan Healthcare Conference

Luminex Corporation announced 2019 highlights and 2020 guidance.

January 12, 2020
·
4 min read
Business

Hologic Announces Preliminary Financial Results for First Quarter of Fiscal 2020

Hologic, Inc. announced preliminary revenue results for its first fiscal quarter ended December 28, 2019.

January 12, 2020
·
5 min read
Business

Baxter Announces Preliminary Net Sales for the Fourth-Quarter and Full-Year 2019 and Announces Preliminary Full-Year 2020 Guidance

Baxter International Inc. announced preliminary net sales for the quarter and full year ended December 31, 2019, and preliminary full-year 2020 guidance for select financial metrics.

January 12, 2020
·
16 min read
Biotech Bay

Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outlook

OPTIC phase 1 trial progressing with plans to complete patient dosing in cohort three, begin enrollment in cohort four in 1Q20

January 12, 2020
·
6 min read
Business

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Total Epidiolex® preliminary net product sales of approximately $104 million for the fourth quarter and approximately $296 million for the first full year of sales

January 12, 2020
·
6 min read
Business

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Product Revenues and Provides Additional Commercial Updates

Achieved Fourth Quarter and Full Year 2019 ONPATTRO® (patisiran) Preliminary Global Net Product Revenues of Approximately $56 Million and $166 Million, Respectively

January 12, 2020
·
14 min read
Business

NanoString Provides Preliminary Operational and Financial Results for Fourth Quarter and FY 2019

FY19 Product and Service Revenue of $103.7 million, including GeoMx DSP Revenue of $10.8 million, Exceeds High End of Guidance Ranges

January 12, 2020
·
6 min read
Business

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones

INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $238 Million with Approximately 42,100 TRx

January 12, 2020
·
10 min read